2016
The impact of broader regional sharing of livers: 2‐year results of “Share 35”
Edwards EB, Harper AM, Hirose R, Mulligan DC. The impact of broader regional sharing of livers: 2‐year results of “Share 35”. Liver Transplantation 2016, 22: 399-409. PMID: 26890858, DOI: 10.1002/lt.24418.Peer-Reviewed Original ResearchConceptsWaiting list mortalityLiver transplantLiver diseaseEnd-stage liver disease candidatesEnd-stage liver diseasePosttransplant survival outcomesChronic liver diseaseCold ischemia timeShare 35 policyRegional sharingBroader regional sharingPost-policy periodPosttransplant graftUrgent groupIschemia timePatient survivalSurvival outcomesMedian MELDMortality rateSickest candidatesOrgan procurementTransplantation NetworkTransplantAge groupsUrgent patients
2011
A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C
Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, Mulligan DC, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinkhabwala M, Koneru B, Abecassis M, Millis M, Jennings LW, Fasola CG. A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transplantation 2011, 17: 1394-1403. PMID: 21850690, DOI: 10.1002/lt.22417.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAntibodies, Monoclonal, HumanizedAntiviral AgentsBiopsyChi-Square DistributionDaclizumabDrug Therapy, CombinationFemaleGraft RejectionHepacivirusHepatitis C, ChronicHumansImmunoglobulin GImmunosuppressive AgentsKaplan-Meier EstimateLiver FailureLiver TransplantationMaleMiddle AgedMycophenolic AcidProportional Hazards ModelsProspective StudiesRecurrenceRisk AssessmentRisk FactorsRNA, ViralSurvival RateTacrolimusTime FactorsTreatment OutcomeUnited StatesConceptsAcute cellular rejectionSteroid-free immunosuppressionLiver transplant recipientsHCV recurrenceMycophenolate mofetilTransplant recipientsHCV RNA-positive subjectsHepatitis C virus infectionSevere HCV recurrenceSteroid-free groupC virus infectionChronic hepatitis CGraft survival ratesProportion of patientsLiver biopsy samplesCellular rejectionChronic HCVStandard immunosuppressionSteroid sparingHepatitis CLess diabetesMulticenter trialMulticenter studyPatient survivalArm 1
2009
Natural history of post–liver transplantation hepatitis C: A review of factors that may influence its course
Gallegos‐Orozco J, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Mulligan D, Moss A, de Petris G, Williams JW, Rakela J, Vargas HE. Natural history of post–liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transplantation 2009, 15: 1872-1881. PMID: 19938138, DOI: 10.1002/lt.21954.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdultBiopsyDisease ProgressionFemaleGraft RejectionHepatitis CHumansKaplan-Meier EstimateLiver CirrhosisLiver FailureLiver TransplantationLiving DonorsMaleMiddle AgedProportional Hazards ModelsRecurrenceRetrospective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTreatment OutcomeConceptsEnd-stage liver diseaseHCV-positive recipientsLiver transplantHepatocellular carcinomaHCV recurrenceAcute rejectionPatient survivalBiopsy-proven acute rejectionMedian age 53 yearsHistory of HCCAggressive HCV recurrenceEarly acute rejectionProtocol liver biopsiesSignificant HCV recurrenceAdult liver transplantsAdvanced donor ageAge 53 yearsAge 39 yearsDay of transplantationLong-term survivalElectronic medical recordsAvoidance of rejectionEvaluable populationRapid fibrosersHepatitis CLiving donor liver transplantation and donor graft size: How small can we go to reduce risk to the donor and what is the cost to the recipient?
Mulligan D. Living donor liver transplantation and donor graft size: How small can we go to reduce risk to the donor and what is the cost to the recipient? Liver Transplantation 2009, 15: 1392-1394. PMID: 19877257, DOI: 10.1002/lt.21922.Peer-Reviewed Original Research
2007
Coccidioidomycosis masked by symptoms of end‐stage liver disease in transplant candidates
Sachdev MS, Blair JE, Mulligan DC, Kusne S. Coccidioidomycosis masked by symptoms of end‐stage liver disease in transplant candidates. Transplant Infectious Disease 2007, 9: 153-155. PMID: 17462003, DOI: 10.1111/j.1399-3062.2007.00215.x.Peer-Reviewed Original Research
2006
Model for end‐stage liver disease (MELD) exception for portopulmonary hypertension
Krowka MJ, Fallon MB, Mulligan DC, Gish RG. Model for end‐stage liver disease (MELD) exception for portopulmonary hypertension. Liver Transplantation 2006, 12: s114-s116. PMID: 17123283, DOI: 10.1002/lt.20975.Peer-Reviewed Original ResearchModel for end‐stage liver disease (MELD) exception for hepatopulmonary syndrome
Fallon MB, Mulligan DC, Gish RG, Krowka MJ. Model for end‐stage liver disease (MELD) exception for hepatopulmonary syndrome. Liver Transplantation 2006, 12: s105-s107. PMID: 17123282, DOI: 10.1002/lt.20971.Peer-Reviewed Original Research
2005
Hepatic B‐cell non‐Hodgkin's lymphoma of MALT type in the liver explant of a patient with chronic hepatitis C infection
Orrego M, Guo L, Reeder C, De Petris G, Balan V, Douglas DD, Byrne T, Harrison E, Mulligan D, Rodriguez‐Luna H, Moss A, Reddy K, Rakela J, Vargas HE. Hepatic B‐cell non‐Hodgkin's lymphoma of MALT type in the liver explant of a patient with chronic hepatitis C infection. Liver Transplantation 2005, 11: 796-799. PMID: 15973702, DOI: 10.1002/lt.20384.Peer-Reviewed Original ResearchConceptsLiver transplantationHodgkin's lymphomaB cellsChronic hepatitis C infectionHepatitis C virus infectionHepatic B cellsC virus infectionHepatitis C infectionMarginal zone lymphomaC infectionCirrhotic patientsVirus infectionB-NHLLiver explantsMALT typeLymphomaClinical settingCommon typePatientsInfectionComplicationsTransplantation